Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae:: A case-control study

被引:167
作者
Ho, PL
Tse, WS
Tsang, KWT
Kwok, TK
Ng, TK
Cheng, VCC
Chan, RMT
机构
[1] Univ Hong Kong, Queen Mary Hosp, Div Infect Dis, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Div Infect Dis, Dept Med, Pokfulam, Hong Kong, Peoples R China
[3] Princess Margaret Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1086/319222
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A case-control study was conducted to identify the risk factors associated with levofloxacin-resistant Streptococcus pneumoniae (LRSP) colonization or infection. Twenty-seven case patients (patients with LRSP) were compared with 54 controls (patients with levofloxacin-susceptible S. pneumoniae). Risk factors that were significantly associated with LRSP colonization or infection, according to univariate analysis, included an older age (median age, 75 years for case patients versus 72.5 years for controls), residence in a nursing home (odds ratio [OR], 7.2), history of recent (OR, 4.6) and multiple (OR, 4.4) hospitalizations, prior exposure to fluoroquinolones (OR, 10.6) and beta -lactams (OR, 8.6), presence of chronic obstructive pulmonary disease (COPD; OR, 5.9), and nosocomial origin of the bacteria (OR, 5.7). Multivariate analysis showed that presence of COPD (OR, 10.3), nosocomial origin of the bacteria (OR, 16.2), residence in a nursing home (OR, 7.4), and exposure to fluoroquinolones (OR, 10.7) were independently associated with LRSP colonization or infection. Thus, a distinct group of patients with COPD is the reservoir of LRSP.
引用
收藏
页码:701 / 707
页数:7
相关论文
共 42 条
  • [1] Safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre study
    Allegra, L
    Konietzko, N
    Leophonte, P
    Hosie, J
    Pauwels, R
    Guyen, JN
    Petitpretz, P
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 : 93 - 104
  • [2] Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy
    Andrews, JM
    Honeybourne, D
    Jevons, G
    Brenwald, NP
    Cunningham, B
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (04) : 573 - 577
  • [3] Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae
    Barry, AL
    Brown, SD
    Fuchs, PC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (03) : 428 - 429
  • [4] Community-acquired pneumonia in adults: Guidelines for management
    Bartlett, JG
    Breiman, RF
    Mandell, LA
    File, TM
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 811 - 838
  • [5] COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE
    BLASER, J
    STONE, BB
    GRONER, MC
    ZINNER, SH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) : 1054 - 1060
  • [6] CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
  • [7] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [8] Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis
    Chodosh, S
    McCarty, J
    Farkas, S
    Drehobl, M
    Tosiello, R
    Shan, M
    Aneiro, L
    Kowalsky, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 722 - 729
  • [9] Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
    Chodosh, S
    Schreurs, A
    Siami, G
    Barkman, HW
    Anzueto, A
    Shan, M
    Moesker, H
    Stack, T
    Kowalsky, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 730 - 738
  • [10] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10